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Impact of comorbid conditions on asthmatic adults
and children
Alan Kaplan1✉, Stanley J. Szefler2 and David M. G. Halpin 3
Comorbid conditions (comorbidities) can complicate the diagnosis and management of asthma. In different age groups, comorbid
conditions can present varying challenges, including diagnostic confusion due to mimicking asthma symptoms, exacerbation of
asthma symptoms, therapy for comorbid conditions affecting asthma or therapy for asthma affecting these conditions. This review
aims to summarise some common comorbid conditions with asthma, such as rhinitis, vocal cord dysfunction, gastro-oesophageal
reflux, psychiatric disorders, obesity and obstructive sleep apnoea, and discuss their prevalence, symptoms, diagnosis and
treatment, highlighting any differences in how they impact children and adults. Overall, there is a lack of data on the impact of
treating comorbid conditions on asthma outcomes and further studies are needed to guide age-appropriate asthma management
in the presence of these conditions.
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INTRODUCTION
Comorbid conditions (comorbidities) in asthma—such as rhinitis,
vocal cord dysfunction (VCD), gastro-oesophageal reflux disease
(GERD), psychiatric disorders, obesity and obstructive sleep
apnoea (OSA)—are common and often overlooked, leading to
clinical confusion and complication of diagnosis1. Despite wide-
spread occurrence, there does not appear to be a consensus on
the definition of comorbid conditions in the literature2. They are
sometimes defined as coexisting conditions and sometimes as
conditions with causal connection, or in some instances, both2–4.
In this review, we define comorbid conditions as disorders or
diseases that are frequently present in a patient in addition to
asthma. The comorbid conditions discussed may or may not have
aetiological association with asthma, but their presence may
nonetheless cause challenges in asthma management.
For patients with asthma, comorbid conditions carry a major
economic burden. In the United States, 54% of adults with asthma
in a nationally representative sample reported having ≥1 non-
respiratory comorbid condition5. In a similar study in the UK on
the prevalence of physical and mental health comorbid condi-
tions, 63% of adults with asthma had ≥1 comorbid condition6.
Furthermore, the number and prevalence of asthma comorbid
conditions increases with age7, which is of particular concern
given the globally ageing population8. Asthma comorbid condi-
tions are associated with substantial healthcare costs that are five
times higher than costs attributable to asthma alone9. On top of
the direct costs, asthma comorbid conditions are associated with
worse asthma-related outcomes5,10, increased risk of work
disability11 and significant productivity losses12, further contribut-
ing to the burden of the disease.
Comorbid conditions can complicate the diagnosis and
management of patients with asthma. Their symptoms may be
similar to those associated with poor asthma control, which can
lead to misdiagnosis and undertreatment or overtreatment. For
example, obesity and asthma both cause breathlessness, putting
patients at risk of a misdiagnosis. In fact, in one study, 36% of
obese patients with physician-diagnosed asthma had no bronchial
hyperresponsiveness, indicating a possible misdiagnosis13. As with
obesity, comorbid conditions can also have a direct impact on
respiratory symptoms, and their treatment can give rise to
potential adverse events (AEs) associated with therapy6,14. For
example, β-blockers for the management of cardiovascular
disease, ocular hypertension or anxiety are avoided in asthma
due to concerns over acute bronchoconstriction6,15,16.
Comorbid conditions are likely to lead to polypharmacy14,
which in turn may have a negative impact on treatment
adherence and asthma control17. Some asthma treatments may
also increase the risk of developing comorbid conditions: inhaled
corticosteroids (ICSs) in high doses can lead to osteoporosis18 and
increase the risk of developing diabetes and pulmonary non-
tuberculous mycobacterial infection19,20. There is therefore a
potentially complex interplay between treatments and comorbid-
ities; decision-making must take into consideration and balance
potential benefits of treatment on one condition with the
potential disadvantages on a comorbid condition.
Over the life course of patients with asthma, the prevalence and
type of comorbid conditions may vary, further complicating
asthma diagnosis and management. It is essential that clinicians
treating patients with asthma understand all the comorbid
conditions that are associated with asthma and identify their
impact on different age groups. This will enable physicians and
healthcare providers to recognise and manage asthma comorbid
conditions in the most efficient and effective way. In this review,
using literature searches on PubMed to identify review articles and
manuscripts (initial search terms included ‘asthma[Title] AND
comorbid*[Title]’, which were expanded as needed to identify
literature), the authors critically review the literature and use their
clinical knowledge and understanding to identify the comorbid-
ities that are most frequently reported. During the review’s
development, the authors held meetings to discuss and reach a
consensus on which comorbidities were common and which
would be discussed within the review. The authors acknowledge
that most literature sources are from high-income countries (HICs),
and therefore certain comorbidities that are more frequent in
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low- and middle-income countries (LMIC), for example, tubercu-
losis (TB), may not be discussed in this review. We define common
comorbidities as those that are most frequently reported in
literature and clinical practice from HICs.
The overall aim of this review is to explore common comorbid
conditions of asthma and highlight any differences in how they
impact children and adults. The common comorbid conditions
discussed in the review are summarised in Table 1. The complex
interplay between comorbid conditions and aspects of asthma in
adults and children is highlighted in Fig. 1. It emphasises that
there may be comorbidities that need to be addressed in parallel
to aspects of asthma in order to achieve effective asthma
management, there may be comorbidities that complicate the
diagnosis of asthma and the relative importance of these factors
varies in adults and children.
RHINITIS
Prevalence
The prevalence of rhinitis in patients with asthma ranges from 6 to
95%, with the variability attributed to lack of standardisation in
establishing a rhinitis diagnosis21. The literature suggests that
both children and adults with asthma and comorbid rhinitis have
more frequent physician visits, emergency room visits and
hospital admissions and higher asthma-related drug expenses22.
Upper airway pathologies such as nasal polyps often accompany
asthma23. The presence of nasal polyps in asthma patients is
associated with a more severe asthma phenotype as well as
aspirin intolerance23 and may affect how asthma and other
comorbid conditions are treated.
Symptoms and diagnosis
Nasal itching, sneezing, increased nasal secretions, nasal obstruc-
tion and cough are common symptoms in patients with allergic
rhinitis. However, rhinitis may also cause less obvious symptoms,
such as lassitude and sleepiness, as a consequence of sleep
disturbances3,24. If these are the presenting symptoms, the
diagnosis of allergic rhinitis may be missed if the patient or
caregiver is not actively questioned about nasal symptoms3. In a
study in the USA, 53% of children with asthma and comorbid
allergic rhinitis remained undiagnosed until they were clinically
evaluated for the study25. Similar rates of underdiagnosis
(32–45%) have also been reported in adults26 and could be due
to under-reporting by patients or caregivers and poor recognition
of rhinitis symptoms by physicians27.
As rhinitis and asthma tend to coexist, the Allergic Rhinitis and
its Impact on Asthma guidelines highlight the importance of
routinely investigating the presence of asthma in patients with
persistent rhinitis28. Similarly, the Global Initiative for Asthma’s
(GINA’s) Global Strategy for Asthma Management and Prevention
and the National Asthma Education and Prevention Program’s
Expert Panel Report for the diagnosis and management of asthma
recommend an evaluation for comorbid allergic rhinitis in patients
with asthma, especially in severe asthma26,29. Evaluation entails
enquiring into patient history and making a physical examination.
Patient history should include careful attention to environmental
exposures, with a focus on precipitating factors and the impact of
symptoms on quality of life26. Validated questionnaires such as the
Total Nasal Symptom Score and Sinonasal Questionnaire may be
used to give an objective assesssment1,30,31. Physical examination
may show rhinorrhoea, enlargement and pallor of the inferior
nasal turbinates, conjunctival infection and increased lacrimation
(which are usually features of co-existent acute conjunctivitis),
Dennie–Morgan lines (a fold in the skin below the lower eyelid),
allergic shiners (dark circles under the eyes resembling bruises), a
transverse nasal crease, sinus tenderness and nasal polyps23,26.
Sensitisation to suspected allergens can be assessed by testing for
allergen-specific immunoglobulin E (IgE) antibodies or allergen
skin prick testing26. In vitro assays for serum allergen-specific IgE
can be performed for patients who cannot have skin testing due
to dermatographism or recent oral antihistamine use26. However,
results of such allergen testing can be difficult to interpret in
patients with asthma and may simply reflect exposure rather than
causation of the symptoms.
Impact of treatment on asthma outcomes
There is conflicting evidence on the benefits of adequately
treating rhinitis in terms of its impact on asthma outcomes. One
meta-analysis reported no significant improvement in asthma
symptoms or lung function by treating rhinitis with intranasal
corticosteroids, even though a trend in improvement was noted32.
Other studies have shown that treatment does improve disease
control and quality of life in asthma patients22. For example, in
adults, the use of nasal corticosteroids was associated with a
significantly reduced risk of asthma-related emergency room
treatments and hospitalisations (adjusted odds ratio 0.75 [95%
confidence interval (CI) 0.62–0.91] and 0.56 [95% CI 0.42–0.76],
respectively)3. However, no similar studies have been reported in
children3.
Additional considerations
Consideration should be given to optimal management of sleep
disturbances including sleep apnoea (a common comorbid
condition in asthma) as a consequence of upper airway
obstruction in patients with persistent asthma and comorbid
rhinitis4. Sleep disturbances can lead to tiredness, irritability,
memory deficit, daytime sleepiness and depression, thereby
reducing quality of life24.
Top tips for identifying rhinitis in primary care
● Patients may accept rhinitis as their ‘normal’, yet it can affect
quality of life. Nasal congestion, rhinorrhoea and smell
restrictions may be common, identifiable symptoms.
VOCAL CORD DYSFUNCTION
Prevalence
The prevalence of VCD is difficult to determine as it is a dynamic,
episodic condition that may not be easily provoked at the time of
examination4. In a study on patients with difficult-to-treat asthma,
VCD was present in 50% of the patients as confirmed by
computerised tomography33. Another study reported the pre-
valence of VCD, examined via laryngoscopy, to be 19% in patients
with asthma34.
Symptoms and diagnosis
The symptoms of VCD include chest tightness (which may be
described as originating superior to the sternal notch), wheezing
(may be high pitched and musical or stridulous), hoarseness,
dysphonia, cough and globus pharyngeus4. These symptoms may
be provoked by respiratory or laryngeal irritants, exercise stress,
anxiety or even by frequent use of inhalers4. These symptoms also
overlap with asthma symptoms, which can lead to both inaccurate
diagnosis and incorrect assessment of the severity of the asthma1.
VCD is often suspected by the increase in the level of symptoms
at the time of physical examination and by the presence of
audible wheeze from the mouth over the lung fields on
auscultation35. Diagnosis of VCD can be difficult to confirm as
physical examination and spirometry may be normal between
episodes36. It is also important to exclude significant upper airway
A Kaplan et al.
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pathology such as tracheobronchial tumours or subglottic
stenoses before considering a diagnosis of VCD37,38. The gold
standard for diagnosing VCD is endoscopic examination with
direct visualisation of the vocal cords via laryngoscopy, possibly
after bronchial challenge or during an acute attack39. To evaluate
whether vocal cord movement is abnormal, patients should also
be instructed to sniff, verbalise sounds through sequential
phonation, breathe, pant and carry out repetitive deep breaths40.
During spirometry, a truncated inspiratory loop may also help to
diagnose VCD in the presence of symptoms but the predictive
value for this process is low36. Questionnaires such as the
Pittsburgh VCD Index have a good predictive value to diagnose
VCD (cut-off score ≥4) and may be helpful to distinguish VCD from
asthma36. Patients with poor asthma control, frequent exacerba-
tions or inadequate response to treatment should be investigated
for VCD36.
Impact of treatment on asthma outcomes
Treating VCD involves a multidisciplinary approach. Speech
therapy is considered the cornerstone of VCD treatment1,36. Other
therapies such as continuous positive airway pressure (CPAP),
injecting Clostridium botulinum toxin into laryngeal muscles or
psychotherapy have been suggested as beneficial, but no
convincing data exist to support their use1,36.
Identifying and successfully treating VCD can have a significant
impact on asthma outcomes. A recent prospective observational
study showed that diagnosis and treatment of VCD led to a
decline in asthma medication use and improvement of symptoms
in 79 and 82% of patients, respectively41. In another study, speech
pathology treatment for VCD reduced asthma medication use in
80% of female adolescent athletes42.
Additional considerations
The most important issues with VCD are that it is sometimes
misdiagnosed as, and often complicates, asthma1,4. This can lead
to excessive or inappropriate use of asthma medications40.
Top tips for identifying VCD in primary care
● VCD can be difficult to diagnose but should be considered




In a systematic review of studies based on questionnaires,
personal interviews or databases, the prevalence of GERD (defined
as at least weekly heartburn and/or acid regurgitation) in patients
with asthma was 58%43. In studies where GERD was confirmed
through oesophageal pH monitoring, the pooled sample-size-
weighted average prevalence of abnormal oesophageal acid



















Fig. 1 Interplay between comorbid conditions and aspects of asthma in adults and children. The comorbidities described in the figure, if
present in the patient, may complicate the diagnosis of asthma. When seeking to achieve effective asthma management, it is important to
address comorbidities. GERD gastro-oesophageal reflux disease, OSA obstructive sleep apnoea, VCD vocal cord dysfunction.
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Symptoms and diagnosis
In patients with asthma, clinicians should suspect comorbid GERD
if asthma symptoms worsen after certain foods (e.g. chocolate,
alcohol, peppermint, coffee, etc.) or patients experience cough or
wheezing after acidic drinks or food or after a large meal44. Other
symptoms that could indicate comorbid GERD include hoarseness,
predominance of nocturnal symptoms, symptom (heartburn,
regurgitation) occurrence when changing position and unex-
plained dental erosion44,45.
GERD can pose a diagnostic challenge as the disease may have
atypical or extra-oesophageal symptoms, such as chronic cough,
laryngitis and non-cardiac chest pain45. These atypical manifes-
tations can be challenging to diagnose in the absence of the
typical symptoms of heartburn and regurgitation45. Symptoms
such as cough, laryngeal or pharyngeal irritation and chest
tightness overlap with those seen in individuals with asthma
and/or upper airway disease, making the identification of GERD a
challenge, and potentially leading to inappropriate choice of
therapy4,46.
Empiric therapy with twice-daily proton pump inhibitor (PPI) is
the recommended management option in patients suspected of
having GERD-related complications1,47. However, some evidence
suggests that PPI therapy may provide little to no improvement in
asthma control48. To further confirm diagnosis of GERD as a
comorbid condition, specific examinations assessing for GERD,
such as impedance–pH monitoring and/or gastro-oesophageal
endoscopy, can be used39. The American Academy of Allergy
Asthma and Immunology advise that lifestyle changes including
weight loss, a reduction in alcohol consumption and smoking
cessation can help with the management of GERD. In addition,
elevating the head of the bed or advising the patient not to lie
down within 2–3 h of eating may assist in reducing symptoms of
GERD49.
Impact of treatment on asthma outcomes
Improvements in lung function, symptoms and quality of life have
been reported in a few studies of PPI treatment in patients with
asthma and comorbid GERD1,50–54. However, other studies
reported no measurable improvement in asthma control48,55. A
Cochrane review by Chan et al. concluded that there is inadequate
evidence to recommend empirical use of PPIs for routine
treatment in asthma56. Even though evidence of the impact of
treating GERD on asthma outcomes is somewhat conflicting,
referral to a gastroenterologist should be considered if GERD is not
controlled on twice-daily PPI and is required if the patient has
symptoms such as dysphagia, odynophagia, involuntary weight
loss or anaemia1.
Additional considerations
Some asthma therapies may aggravate GERD and even, para-
doxically, worsen asthma control57. For example, theophylline,
albuterol and bronchodilators may decrease lower oesophageal
sphincter tone leading to increased GERD, systemic corticosteroids
may increase gastric acid production and ICS may lead to
hoarseness similar to that caused by GERD4. GERD is also a
frequent complication of pregnancy and is reported to be more
severe in pregnant women with asthma than in pregnant women
without asthma58.
Top tips for identifying GERD in primary care
● While classic symptoms of heartburn and food and acid reflux
may be present, they may also be absent. Therefore, it is
important to look for any unexpected dental issues and
changes in the patient’s voice.
PSYCHIATRIC DISEASES
Prevalence
Estimates of the prevalence of psychological disturbances among
patients with asthma vary widely. A World Health Organization
survey of psychiatric comorbid conditions in 85,000 patients with
asthma, using a standardised, structured psychiatric interview with
trained interviewers, reported an estimated prevalence of 2–26%
for major depression59. In the same study, age-matched patients
without asthma had an estimated prevalence of 1–9% for major
depression59. Anxiety is also a commonly reported comorbidity in
patients, with 1 Italian study in 263 outpatients with asthma
reporting that a third of patients had anxiety. Furthermore, the
authors reported that patients who report anxiety have a greater
perception of worse asthma control than those with no anxiety60.
The prevalence of comorbid mental and behavioural disorders
appears to increase with age. For example, in a study using routine
healthcare data of German children and adolescents with asthma,
the prevalence of depression increased from 0.3 to 3% and anxiety
disorder increased from 2 to 5% between 6–9- and 14–17-year-
olds61. In a Spanish National Health survey, factors such as older
age and concomitant comorbid conditions were associated with
higher rates of depression and anxiety in patients with asthma62.
Symptoms and diagnosis
Patients with moderate-to-severe asthma or difficult-to-control
asthma should be assessed for depression, panic and anxiety
disorder. In order to confirm the diagnosis and follow-up
response, it is advised to use a validated questionnaire such as
the Hospital Anxiety and Depression Scale1, the Patient Health
Questionnaire (PHQ-9) for depression and the Generalised Anxiety
Disorder Questionnaire (GAD-7) for anxiety63,64.
Comorbid depressive disorders may commonly go unrecog-
nised and untreated in children with asthma. Even if mental
disorders are recognised, only one in five children with asthma
receive adequate treatment3. In adolescents, risk behaviours are
common and tend to co-occur with peer conflict, troubled
parent–adolescent relationships and mood disorder. Depression,
in particular, can lead to a sense of hopelessness that can
negatively affect adherence65. Due to rapid physical, emotional,
cognitive and social changes in adolescence, managing asthma
and comorbid conditions in this group can be challenging29.
Exploratory and risk-taking behaviours, such as smoking and
inhaled substance use, occur at a higher rate in adolescents with
chronic diseases than in healthy adolescents29,66. It is important to
assess risk behaviours, such as smoking, alcohol and other
substance abuse, in children and adolescents. During consulta-
tions, the GINA strategy recommends that adolescents should be
seen separately from the parent/carer so that sensitive issues, such
as smoking, adherence and mental health, can be discussed
privately and confidentiality agreed29. In case of significant
psychological symptoms, patients should be referred to local
mental health services or resources, as available.
Impact of treatment on asthma outcomes
Only a few studies are available investigating the impact of
pharmacological treatment of comorbid psychiatric diseases on
asthma control. In a 12-week randomised controlled trial in 90
adults with asthma and major depressive disorder, the effect of
antidepressant medications on asthma control was studied versus
placebo67. Although no difference in depression scores was
observed between patients treated with antidepressants and
those on placebo, use of oral corticosteroids was lower in
antidepressant-treated patients and a reduction in depressive
symptoms was associated with an improvement in asthma67.
Another similar, but more recent, trial reported a significant
reduction in Asthma Control Questionnaire score and oral
A Kaplan et al.
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corticosteroid use in 21 patients with more severe asthma on
antidepressant treatment compared with placebo68. Treating
depressive symptoms may improve asthma outcomes, but more
evidence is required.
Additional considerations
Potential effects of asthma medications on mental health should
also be considered. Adverse effects such as mood and behavioural
changes, including manic or depressive states and even frank
psychosis, can occur with large doses of oral corticosteroids69.
Concerns about a possible association between leukotriene
receptor antagonist use and suicide risk were raised based on
post-marketing surveillance reports69. Even though a statistically
significant association was found in patients aged 19–24 years in a
case–control study, the association was no longer significant after
adjusting for potential confounding factors69. In some children,
post-marketing surveillance reports have identified behavioural
and/or neuropsychiatric AEs associated with montelukast use70,
and a possible association with suicide risk has been reported in
adolescents and adults71. Since March 2020, the Food and Drug
Administration has required a boxed warning about the risk of
neuropsychiatric events with montelukast to strengthen an
existing warning72. In addition, the potential effects of medica-
tions for psychiatric diseases on asthma control should be
considered. For instance, β-blockers—a commonly prescribed
treatment for anxiety—are contraindicated in asthma and may
cause exacerbations. The benefit of a treatment for one condition
should, therefore, be quantified against the potential risks of the
comorbidity73.
More important is the potential impact of depression and
anxiety on asthma management. For example, depression may
affect medication adherence74, while anxiety associated with
hyperventilation may result in misinterpretation of symptoms as
asthma75.
Top tips for identifying psychiatric diseases in primary care
● If asthma control is poor, patients should be assessed for




Obesity is a common comorbid condition in both children and
adults with asthma, and it is present in 21–48% of patients with
severe asthma76–79. In the general population, the prevalence of
obesity varies by country and ranges from 4 to 38%80. In a study of
6–17-year-old patients with asthma, obesity appeared to increase
with age (8% in 6–9-year-olds, 14% in 10–13-year-olds and 16% in
14–17-year-olds)61.
Obesity, in itself, is a major public health problem. The
prevalence of obesity has more than quadrupled from 1971 to
2006 in children aged 6–11 years in the USA, as well as increasing
sharply for adolescents3,81. In a more recent survey in 2015–2016
in the USA, the prevalence of obesity was recorded to be 40% in
adults and 19% in adolescents, both exhibiting higher prevalence
rates in 2016 compared with rates in 199982.
Obesity can lead to the development or worsening of asthma
via mechanical, inflammatory and genetic/developmental fac-
tors83. OSA and GERD in obese patients may also lead to worse
asthma symptoms83.
Obesity may impact asthma differently in younger age groups
compared with adults62. Studies have shown that the effect of
obesity is different and more pronounced in early- versus late-
onset asthma. Persistent asthma beginning in childhood may be
significantly complicated by obesity developing later in life62. It
has been suggested that late-onset asthma in an already obese
patient may not be complicated further by obesity, as obesity may
have already been a major factor in its appearance62. However,
results from the Severe Asthma Research Program have shown
that obese late-onset asthmatics are more likely to have been
admitted to the emergency department or intensive care unit
versus non-obese late-onset asthmatics84, suggesting their
symptoms may be accentuated and management more compli-
cated as a result of their disease phenotype. Therefore, it is
important to differentiate between patients having asthma and
becoming obese later and obese patients developing new-onset
asthma62.
Symptoms and diagnosis
Obesity is defined as having a body mass index (BMI) ≥ 30 kg/m269.
Obese patients can present with respiratory symptoms such as
breathlessness on exertion, which may be mistaken for asthma.
Therefore, before making a diagnosis of asthma it is important to
demonstrate the presence of variable airflow limitation69.
Impact of treatment on asthma outcomes
A recent systematic review of 10 randomised controlled trials
explored the effect of weight loss on asthma outcomes in obese
children and adults85. Weight loss interventions ranged from
dietary restrictions to multifactorial interventions with exercise
training and cognitive behavioural therapy, with a duration of
8 weeks to 18 months85. Most of the studies reported improve-
ments in asthma-related quality of life and, to some degree,
asthma control, and the systematic review concluded that weight
loss in asthma patients with comorbid obesity may improve
asthma outcomes85. Evidence for an association between bariatric
surgery and improvements in asthma outcomes—such as
improved Asthma Control Test (ACT) scores, asthma control and
quality of life—have also been reported in some studies86.
Additional considerations
Obese patients with asthma may have a reduced response to
asthma treatments, such as ICS, compared with non-obese
patients87. A specific phenotype of asthma exists in some obese
patients. This is associated with lung function changes due to
breathing at low lung volumes, a systemic inflammatory process
that may possibly influence airways and a reduced response to
asthma medications22. Asthma and obesity can both influence the
onset of GERD and sleep disturbances, which can mimic the
‘obese asthma’ phenotype and lead to misdiagnosis88.
Top tips for identifying obesity in primary care




The prevalence of OSA in children with asthma ranges from 35 to
66%89,90; in adults, prevalence is reported to be 40–50%91,92. In the
general population, estimates of OSA prevalence are in the range
of 3–7%93. OSA is associated with more severe exacerbations in
adults and poorer asthma control in children36. The causes of
developing OSA across age groups are generally different; in
children, enlarged adenoids and tonsils and nasal obstruction
have been identified as primary reasons, whereas in adults, a
A Kaplan et al.
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mixture of aetiological factors such as anatomical variations, age,
male sex, ethnic difference and obesity may lead to increased
collapse potential of the pharyngeal muscles36. Smoking, diabetes,
hypothyroidism, alcohol consumption and medication usage are
all factors that could contribute to OSA36. Two mechanisms have
been proposed for how OSA may impact asthma control: it may
increase neutrophilic airway inflammation or lead to vagal
activation from the collapsed pharynx leading to increased
bronchial hyperresponsiveness94.
Symptoms and diagnosis
OSA is characterised by total or partial repetitive obstruction of
the upper airway during sleep, leading to poor quality of sleep,
with symptoms such as brief paroxysmal nocturnal dyspnoea,
choking during sleep, daytime sleepiness, depression and memory
loss36,94,95. OSA may also aggravate or mimic asthma symp-
toms36,94, and both asthma and OSA are associated with airway
obstruction and have many diurnal and nocturnal symptoms in
common95.
Polysomnography is the gold standard for diagnosing OSA94.
However, if polysomnography is not available, overnight pulse
oximetry can also be used as a screening tool96. Validated
questionnaires such as the Epworth Sleepiness Score, STOP-Bang
or the Berlin Questionnaire are also available for screening of
OSA94. In particular, special attention should be given to screening
OSA in children with asthma and coexisting allergic rhinitis, as well
as adenotonsillar hypertrophy36,97. In the severe asthma popula-
tion, patients with OSA may not have classic symptoms of sleep
apnoea and diagnosis may be overlooked94.
Impact of treatment on asthma outcomes
CPAP is the first line of treatment for OSA and its use can have a
positive impact on asthma outcomes98. In a survey-based study
where asthmatic patients with OSA initiated CPAP therapy after
starting asthma medication, there was a significant reduction in
self-reported asthma severity and the number of patients using
rescue medication and an increase in ACT score99. Larger multi-
country observational studies are required to fully evaluate the
impact of CPAP on asthma outcomes.
Additional considerations
Poorly controlled OSA adversely affects sleep, mood and lung
function, so treatment is paramount36,94,95.
Top tips for identifying OSA in primary care
● Patients who are identified to snore or who have unrestorative
sleep with other comorbidities, such as diabetes, cardiovas-
cular disease and obesity, are at high risk of OSA100. Therefore,
the STOP-Bang screening tool101 or Epworth Sleepiness Score
(used as a scale to measure sedation)102 are useful tools
for OSA.
OTHER COMORBID CONDITIONS IN CHILDREN
Other common comorbid conditions in children with asthma
include chronic sinusitis and respiratory infections103. Infants with
food allergies have approximately double the chance of developing
asthma before they reach school age104, and comorbid food allergy
is a significant risk factor for life-threatening asthma; in a small study,
52.6% (n= 10) of severe asthma cases had food allergy compared
with only 10.5% (n= 4) of the controls (P= 0.006)105. Regular
assessments are required in these patients, including dietary and
emergency management plans, and treatment adherence
reviews106.
Top tips for identifying other comorbid conditions in children in
primary care
● The effect of comorbidities in paediatric patients with asthma
who have a history of hives, anaphylaxis and food intolerances
should be considered.
OTHER COMORBID CONDITIONS IN ADULTS
Multimorbidity is common in adults with asthma and the number
of comorbid conditions in asthma increases as patients age62,107.
The types of comorbid conditions differ by age; for example, in a
sample population of >1 million patients with asthma, 47% of
adults aged ≥55 years suffered from comorbid hypertension
compared with 12% in 18–55-year-olds and 0.1% aged <18
years108. The prevalence of comorbid diabetes, congestive heart
failure and fluid and electrolyte disorders was also significantly
higher in the ≥55-year age group, followed by 18–55 years and
then <18 years108. Another study identified hypertension (20.1%),
pain (15.9%), chronic obstructive pulmonary disease (COPD;
13.4%) and dyspepsia (10.9%) as the most frequent comorbid
conditions in adults with asthma6. COPD, in particular, usually
affects people aged ≥40 years and can coexist with asthma62,108.
The GINA strategy and the Global Initiative for Chronic Obstructive
Lung Disease provide recommendations and treatment guidelines
for patients with asthma–COPD overlap29,62. Some patients with
asthma also have chronic pain, which may be treated with opiates;
however, while hypersensitivity to, or accumulation of, opiates is
associated with respiratory depression, it is a very rare
phenomenon109.
Top tips for identifying other comorbid conditions in adults in
primary care
● It is important to perform a complete history and physical
examination to ensure that any comorbid conditions the
patient may have are considered and evaluated.
DISCUSSION
The presence of comorbid conditions complicates the manage-
ment of asthma in all age groups. As clinical trials generally
exclude elderly patients or asthma patients with serious comorbid
conditions, there is a lack of strong evidence to guide asthma
treatments in these individuals62,69. Many comorbid conditions
may impact asthma directly and some may require medications
that can worsen asthma, such as bronchoconstriction-related AEs
from β-blockers and non-steroidal anti-inflammatory drugs
(NSAIDs)16,110. The presence of diabetes can affect decisions
about the use of systemic corticosteroids, which are known to
cause metabolic complications in glucose homoeostasis, including
insulin resistance and hyperglycaemia20,69. In patients with
osteoporosis, vertebral fractures can impair respiratory capacity69.
In addition, other common age-related problems such as
osteoarthritis, cognitive impairment, poor eyesight, hearing loss
or poor coordination can hamper a patient’s ability to use their
inhaler device correctly69.
As previously discussed, it should be acknowledged that a
potential limitation of this review is that it focuses on
comorbidities most frequently reported in HICs. Therefore,
comorbidities affecting patients with asthma from LMICs may
vary and should be addressed accordingly. For example, in
countries with a high TB burden, treatments for patients with
asthma should be considered carefully as there may be an
increased risk of latent TB reactivation following oral corticoster-
oids or ICS use111,112. Furthermore, symptoms such as chronic
cough may relate to asthma or TB; therefore, if the presence of TB
has been excluded, asthma should be investigated113. In addition
to geographical influencing factors, factors such as medication
A Kaplan et al.
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side effects and age can influence comorbidities and asthma
control and should be considered during clinical decision-making.
In conclusion, comorbid conditions can complicate asthma
management in multiple ways; they may be part of the same
pathophysiological process as asthma (e.g. rhinitis) or may
mimic and/or exacerbate asthma symptoms (e.g. GERD and
VCD). In some cases, comorbid conditions may affect asthma
therapy (e.g. diabetes) or therapy for comorbid conditions may
affect asthma (e.g. β-blockers and NSAIDs). Understanding the
pattern of comorbid conditions across the life course of asthma
patients is important as this will help healthcare professionals to
make accurate diagnoses, facilitate prescription of appropriate
therapy and improve asthma management. Further studies
evaluating changes in comorbid conditions over time and their
impact on asthma control are needed to provide clear age-
related guidance on managing asthma patients with comorbid
conditions.
Reporting summary
Further information on experimental design is available in the
Nature Research Reporting Summary linked to this paper.
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